• FDA approves Janssen’s ketamine-based nasal antidepressant pharmaphorum
    March 07, 2019
    The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to specialist clinics.
  • Allergan acquires NMDA depression drug from Aptinyx collaboration fiercebiotech
    May 29, 2018
  • Aptinyx seeks $80M IPO to push NMDA drug platform fiercebiotech
    May 29, 2018
PharmaSources Customer Service